A novel protein molecule engineered to combat insulin resistance has been developed by an international research consortium. The molecule, designated "Aap2," has shown high efficacy in suppressing insulin resistance and regulating blood glucose levels, presenting a promising new avenue for treating both Type 1 and Type 2 diabetes.

Published in the journal PNAS, the research reveals that Aap2 functions by mimicking the activity of a protein known as ATG7. The team discovered that ATG7 performs a previously unknown and critical role in metabolic regulation, traveling from muscle tissue to the liver to boost glucose uptake in response to insulin.